United States - English - NLM (National Library of Medicine)

virtus pharmaceuticals - ergocalciferol (unii: vs041h42xc) (ergocalciferol - unii:vs041h42xc) - ergocalciferol 0.2 mg in 1 ml - contraindicated in people with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin d, and hypervitaminosis d.

Malta - English - Medicines Authority

boston healthcare limited unit 6, navigation court, calder park, wakefield, west yorkshire wf2 7jb, united kingdom - ergocalciferol, ascorbic acid, nicotinamide, thiamine hydrochloride, pyridoxine hydrochloride, retinol palmitate, riboflavin - oral drops, solution - ergocalciferol 400 u ascorbic acid 50 mg nicotinamide 5 mg thiamine hydrochloride 1 mg pyridoxine hydrochloride 500 µg retinol palmitate 5000 u riboflavin 400 µg - vitamins

United States - English - NLM (National Library of Medicine)

hospira, inc. - ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), retinol (unii: g2sh0xkk91) (retinol - unii:g2sh0xkk91), ergocalciferol (unii: vs041h42xc) (ergocalciferol - unii:vs041h42xc), thiamine hydrochloride (unii: m572600e5p) (thiamine ion - unii:4abt0j945j), riboflavin 5'-phosphate sodium (unii: 20rd1dzh99) (flavin mononucleotide - unii:7n464ure7e), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z), niacinamide (unii: 25x51i8rd4) (niacinamide - unii:25x51i8rd4), de - ascorbic acid 80 mg in 5 ml - m.v.i. pediatric is a combination of vitamins indicated for the prevention of vitamin deficiency in pediatric patients up to 11 years of age receiving parenteral nutrition. the physician should not await the development of clinical signs of vitamin deficiency before initiating vitamin therapy. m.v.i. pediatric is contraindicated in patients who have: - a history of known hypersensitivity to any of the vitamins or excipients in m.v.i. pediatric [see warnings and precautions (5.2), adverse reactions (6)] - an existing hypervitaminosis the safety and effectiveness of m.v.i. pediatric for the prevention of vitamin deficiency have been established in pediatric patients up to 11 years of age receiving parenteral nutrition. the safety and effectiveness of m.v.i. pediatric have not been established in pediatric patients older than 11 years of age. m.v.i. pediatric contains aluminum that may be toxic for premature neonates. aluminum levels should be monitored periodically during administration of m.v.i. pediatric to p

United States - English - NLM (National Library of Medicine)

hospira, inc. - retinol (unii: g2sh0xkk91) (retinol - unii:g2sh0xkk91), ergocalciferol (unii: vs041h42xc) (ergocalciferol - unii:vs041h42xc), .alpha.-tocopherol acetate, dl- (unii: wr1wpi7ew8) (.alpha.-tocopherol, dl- - unii:7qwa1rio01), phytonadione (unii: a034se7857) (phytonadione - unii:a034se7857), ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), niacinamide (unii: 25x51i8rd4) (niacinamide - unii:25x51i8rd4), riboflavin 5'-phosphate sodium (unii: 20rd1dzh99) (flavin mononucleotide - unii:7n464 - retinol 1 mg in 5 ml - m.v.i. adult™ is a combination of vitamins indicated for the prevention of vitamin deficiency in adults and pediatric patients aged 11 years and above receiving parenteral nutrition. the physician should not await the development of clinical signs of vitamin deficiency before initiating vitamin therapy. m.v.i. adult is contraindicated in patients who have: risk summary administration of the approved recommended dose of m.v.i. adult in parenteral nutrition is not expected to cause major birth defects, miscarriage, or adverse maternal or fetal outcomes. pregnant women should follow the u.s. recommended daily allowances for pregnancy because their vitamin requirements may exceed those of nonpregnant women. deficiency of essential vitamins may result in adverse pregnancy outcomes (see clinical considerations) . animal reproduction studies have not been conducted with m.v.i. adult administered by intravenous infusion. the estimated background risk of major birth defects and miscarriage for the indicated population

United States - English - NLM (National Library of Medicine)

kaiser foundation hospitals - ergocalciferol (unii: vs041h42xc) (ergocalciferol - unii:vs041h42xc) - ergocalciferol 1.25 mg - ergocalciferol capsules, usp are indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin d resistant rickets, and familial hypophosphatemia. ergocalciferol capsules, usp are contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin d, and hypervitaminosis d.

United States - English - NLM (National Library of Medicine)

breckenridge pharmaceutical, inc. - ergocalciferol (unii: vs041h42xc) (ergocalciferol - unii:vs041h42xc) - ergocalciferol 1.25 mg - ergocalciferol capsules, usp are indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin d resistant rickets, and familial hypophosphatemia. ergocalciferol capsules, usp are contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin d, and hypervitaminosis d.

United States - English - NLM (National Library of Medicine)

american health packaging - ergocalciferol (unii: vs041h42xc) (ergocalciferol - unii:vs041h42xc) - ergocalciferol 1.25 mg - ergocalciferol capsules, usp are indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin d resistant rickets, and familial hypophosphatemia. ergocalciferol capsules, usp are contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin d, and hypervitaminosis d.

United States - English - NLM (National Library of Medicine)

st marys medical park pharmacy - ergocalciferol (unii: vs041h42xc) (ergocalciferol - unii:vs041h42xc) - ergocalciferol 1.25 mg - ergocalciferol capsules, usp are indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin d resistant rickets, and familial hypophosphatemia. ergocalciferol capsules, usp are contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin d, and hypervitaminosis d.

United States - English - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - ergocalciferol (unii: vs041h42xc) (ergocalciferol - unii:vs041h42xc) - ergocalciferol 1.25 mg - ergocalciferol capsules, usp are indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin d resistant rickets, and familial hypophosphatemia. ergocalciferol capsules, usp are contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin d, and hypervitaminosis d.

United States - English - NLM (National Library of Medicine)

blenheim pharmacal, inc. - ergocalciferol (unii: vs041h42xc) (ergocalciferol - unii:vs041h42xc) - ergocalciferol 1.25 mg - ergocalciferol capsules, usp are indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin d resistant rickets, and familial hypophosphatemia. ergocalciferol capsules, usp are contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin d, and hypervitaminosis d.